Indicative Timing Clause Samples

The Indicative Timing clause sets out estimated timeframes for the completion of certain tasks or milestones within an agreement. It typically outlines when key deliverables are expected, such as project phases, delivery dates, or review periods, providing a schedule for both parties to reference. While these timings are not usually binding deadlines, the clause helps manage expectations and facilitates planning by giving all parties a shared understanding of the anticipated timeline.
POPULAR SAMPLE Copied 1 times
Indicative Timing. Based upon this Letter and the terms and conditions discussed herein, we would expect to be able to achieve the following timetable. |_| On or before 3 April 2006 it is anticipated that new management and Emerging Gamma will agree to the general terms as outlined. |_| The documents will be executed by April 7, 2006. |_| In April, we will begin with low intensity investor relations / public relations campaigns. |_| Mid to late May 2006, it is anticipated that, based on a successful funding operation, new management will have raised investment of US$ 3 million in the US capital markets. Additionally, new management may choose to seek banking facilities to leverage accounts receivables and to initiate a revolving line of credit. New management will begin trading on the OTC market. |_| Late May to June, New Management will seek to place the initial orders for finished product supply and begin to execute its business plan. Please sign and date this Letter no later than 3 April 2006, in the space provided below to confirm our mutual understandings and agreements as set forth in this Letter and return a sign copy to the undersigned. By signing this Letter, you are representing that you have the authority to consummate this transaction. This is a binding statement of our intentions, subject to and conditional on (i) Emerging Gamma's satisfactory completion of due diligence and (ii) preparation and execution of definitive documents to implement the plan set forth herein. If this letter is acceptable, please sign a return a copy. Very truly yours, For and on Behalf of New Management ___________________________________ Date: April 3, 2006 Accepted and agreed: Emerging Gamma Corporation By:____________________________ Allen F. Campbell, President Date: April 3, 2006
View Source

Related to Indicative Timing

  • Five-Tier Copayment Structure This prescription drug plan formulary has a five-tiered copayment structure. The copayment for a prescription drug will vary by tier. The tier placement of a prescription drug on our formulary is subject to change. For more information about our formulary, and to see the tier placement of a particular prescription drug, visit our website or call our Customer Service Department. Below indicates the tier structure for this plan and the amount that you are responsible to pay. You will be responsible for paying the lowest cost of either your copayment, the retail cost of the drug, or the pharmacy allowance. We reserve the right not to accept manufacturer coupons, discount plan payments or other cost share assistance program payments for prescription drug copayments and/or deductibles.

  • Classification Structure All employees working under this Agreement shall be classified according to the skill based classification structure set out in Appendix A.

  • Target Population TREATMENT FOR ADULT (TRA) Target Population

  • Governance Structure The Academy shall be organized and administered under the direction of the Academy Board and pursuant to the governance structure as set forth in its Bylaws. The Academy’s Board of Directors shall meet at least six times per fiscal year, unless another schedule is mutually agreed upon by the University President or Designee and the Academy.

  • Corporate Transactions The effective date of a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination involving the Company and one or more businesses (a “Business Combination”), in each case, unless, following such Business Combination: (1) all or substantially all of the individuals and entities who were the Beneficial Owners of securities entitled to vote generally in the election of directors immediately prior to such Business Combination beneficially own, directly or indirectly, more than 51% of the combined voting power of the then outstanding securities of the Company entitled to vote generally in the election of directors resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more Subsidiaries (as defined below)) in substantially the same proportions as their ownership immediately prior to such Business Combination, of the securities entitled to vote generally in the election of directors; (2) other than an affiliate of the Sponsor, no Person (excluding any corporation resulting from such Business Combination) is the Beneficial Owner, directly or indirectly, of 15% or more of the combined voting power of the then outstanding securities entitled to vote generally in the election of directors of the surviving corporation except to the extent that such ownership existed prior to the Business Combination; and (3) at least a majority of the Board of Directors of the corporation resulting from such Business Combination were Continuing Directors at the time of the execution of the initial agreement, or of the action of the Board of Directors, providing for such Business Combination;